GC Pharma (Formerly known as Green Cross) (KRX: 006280), a South Korean biopharmaceutical company, today announced that it will proceed with a Phase 2/3 clinical trial for GC1102 (also known as Hepabig-gene), the company’s investigational […]
It’s well known that cancer cells can become drug resistant. When this happens, a previously effective treatment will stop working, causing major problems for patient care. What is less well known is that cancer cells […]
MiMedx (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, today announced that the first patients have been randomized […]
Exelixis, (NASDAQ:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results of the pivotal phase 3 CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma (HCC), which will be presented in a late-breaking oral session […]
Pracinostat is an oral histone deacetylase (HDAC) inhibitor that is currently under Phase III clinical trial in combination with azacitidine for adult AML patients who are eligible for induction chemotherapy. The drug candidate received the […]